QuidelOrtho Corporation (QDEL)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1,662 | 1,699 | 3,266 | 2,998 | 2,783 | 2,730 | 2,674 | 2,544 |
| Operating profit | $m | -919 | -820 | ||||||
| Net profit | $m | 810 | 704 | 549 | -10 | -2,052 | -1,132 | -1,048 | 52 |
| EPS reported | $ | -16.69 | -15.44 | ||||||
| Operating cashflow per share | $ | 1.55 | -0.84 | ||||||
| Capex per share | $ | 2.78 | 2.25 | ||||||
| FCF per share | $ | -1.22 | -3.09 | ||||||
| Free cash flow | $m | -83 | -211 | ||||||
| Net debt | $m | 2,448 | 2,800 | ||||||
| Book value equity | $m | 1,921 | 1,775 | ||||||
| Book value per share | $ | 28.33 | 25.99 | ||||||
| Number of shares | m | 67.8 | 68.3 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.03 | 1.12 | ||||||
| P/S LTM | x | 0.73 | 0.74 | ||||||
| P/FCF LTM | x | -23.93 | -9.41 | ||||||
| EV/EBITDA LTM | x | -9.53 | -9.32 | ||||||
| EV/Sales LTM | x | 1.70 | 1.47 | ||||||
| Earnings Yield LTM | % | -56.97% | -1.07% | ||||||
| FCF Yield | % | -4.18% | -10.63% | ||||||
| Quality | |||||||||
| ROE | % | -58.93% | -55.30% | ||||||
| ROIC | % | -18.34% | -16.05% | ||||||
| Operating margin | % | -33.67% | -30.67% | ||||||
| Gross margin | % | +46.67% | +44.60% | ||||||
| FCF/Sales | % | -3.04% | -7.90% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -1.89% | -3.91% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.03 | -0.07 | ||||||
| Net Debt/EBITDA | x | -5.46 | -5.92 | ||||||
| EBIT/Net interest | x | -5.18 | -4.21 | ||||||
| Net debt/market cap | % | +1.33% | +3.00% | ||||||
| Net debt/Equity | x | 1.27 | 1.58 | ||||||
| Gross debt/equity | x | 1.48 | 1.73 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free